Hepatic arterial therapy with oxaliplatin and systemic capecitabine for patients with liver metastases from breast cancer.

•HAT with oxaliplatin in patients with MBC is safe and efficient.•In these phase 2 trials, the overall RR was 42.3%, median PFS 10.8 months, and median OS 27.6 months.•HAT represents a potential loco-regional treatment for liver metastases.•Abdominal pain was only seen after intrahepatic treatment but was manageable.•Besides abdominal pain, toxicity was comparable and manageable between i.v. and HAT administrations.